Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setrusumab in Postmenopausal Women with Low BMD
NCT01406548Phase 2Completed
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Jul 2011
- Primary completion
- Oct 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of setrusumab in osteoporosis and osteopenia (6 arms), sponsored by Ultragenyx Pharmaceutical Inc. Primary endpoints: Change from baseline in bone mineral density at the lumbar spine at 9 months and Number of subjects experiencing adverse events or serious adverse events at 9 months. Started Jul 2011; status: completed.
02
Drugs
setrusumab
03
Conditions
osteoporosisosteopenia
Beyond the preview
Go deeper on NCT01406548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01406548.